Literature DB >> 1983346

Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin.

J T Smith1, C Gavey, C U Nwokolo, R E Pounder.   

Abstract

Simultaneous 24-h intragastric and plasma gastrin concentrations were measured in 36 healthy subjects, when receiving placebo (day 0) and on days 1 and 8 of dosing with either placebo (n = 8), or high-dose H2-blockade with either ranitidine 300 mg q.d.s. (n = 8), ranitidine 1200 mg o.m. (n = 8), or sufotidine 600 mg b.d. (n = 12). Triplicate placebo studies demonstrated good reproducibility for this technique, with no significant differences of acidity or plasma gastrin concentration between the studies. There was a decrease in the anti-secretory activity of all three high-dose H2-antagonist regimens on day 8, when compared with that observed on day 1. This occurred in the presence of sustained or increasing hypergastrinaemia. It is concluded that a degree of tolerance develops during continued H2-blockade, and that this could be due to increasing gastrin drive to the parietal cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1983346

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  15 in total

1.  pH-feedback controlled infusions of ranitidine are no more effective than fixed-dose infusions in reducing gastric acidity and variability in antisecretory responses.

Authors:  C H Wilder-Smith; F Halter; W Häcki; H S Merki
Journal:  Br J Clin Pharmacol       Date:  1992-05       Impact factor: 4.335

2.  Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.

Authors:  C U Nwokolo; J T Smith; A M Sawyerr; R E Pounder
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

3.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

4.  Acid-suppressive effects of various regimens of omeprazole in Helicobacter pylori-negative CYP2C19 homozygous extensive metabolizers: which regimen has the strongest effect?

Authors:  Tomohiko Shimatani; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Susumu Tazuma; Masaki Inoue
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

5.  Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.

Authors:  Malcolm Boyce; Steve Warrington
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

6.  Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.

Authors:  Malcolm Boyce; Steve Warrington; James Black
Journal:  Br J Clin Pharmacol       Date:  2013-11       Impact factor: 4.335

Review 7.  Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing.

Authors:  Johnson W McRorie; James A Kirby; Philip B Miner
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

Review 8.  Antiulcer drugs and gastric cancer.

Authors:  Helge L Waldum; Bjørn Gustafsson; Reidar Fossmark; Gunnar Qvigstad
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

Review 9.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

10.  Impact of long-term ranitidine and pantoprazole on accuracy of [13C]urea breath test.

Authors:  Pietro Dulbecco; Camilla Gambaro; Claudio Bilardi; Patrizia Zentilin; Maria Raffaella Mele; Carlo Mansi; Riccardo Biagini; Laura Tessieri; Elena Iiritano; Paolo Usai; Sergio Vigneri; Vincenzo Savarino
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.